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Summary: Although low density lipoprotein receptors have been described on oligodendrocytes, apolipoprotein B
was thought to be absent or present in only very small amounts in cerebrospinal fluid (CSF). Several immunoassays
have been used for the measurement of apolipoprotein B in serum. However, the majority of methods cannot be
used to measure small amounts of apolipoprotein B in CSF. In this study, we describe a highly sensitive time
resolved immunoftoorometric assay (TR-IFMA) using europium as label (detection limit: 0,3 g/l). The reliability
of the TR-IFMA for the measurement of apolipoprotein B was first studied in serum. Serum and CSF apolipoprotein
B concentrations were then determined in subjects free of neurological disorders and in patients with multiple
sclerosis. Local intrathecal apolipoprotein B synthesis was calculated. Although the high sensitivity of the TR-
IFMA allowed low amounts of apolipoprotein B in CSF to be detected (0.11 ± 0.06; 0.12 ± 0.06 mg/1 in controls
and multiple sclerosis patients, respectively), no apolipoprotein B could be detected in CSF by electroimmunodiffu-
sion. As suggested by the blood/CSF apolipoprotein B ratio (about 6000), no apolipoprotein B synthesis was
observed by both using apolipoprotein B index and formula. This indicates its probable serum origin. Moreover,
there was no difference between controls and multiple sclerosis patients in CSF, serum, blood/CSF, index, and local
intrathecal apolipoprotein B synthesis. Finally, these results suggest that the role of apolipoprotein B in lipid
transport in the central nervous system may be questionable.
Introduction only very small amounts in cerebrospinal fluid (CSF)
_, ,
 A, . - . , . (4) with the exception of cerebrotendinous xanthomato-The central nervous system, together with peripheral \' *
neural tissue, possesses a lipid transport system involv-
ing apolipoproteins which is responsible for maintaining Most immunoassays have been used for the measure-
cholesterol and lipid homeostasis (1). Multiple sclerosis ment of apolipoprotein B in serum (6-9). However, the
is a neurological disease characterized by primary de- most suitable methods, immunoturbidimetric assay and
struction of myelin and followed by marked alterations immunonephelometric assay, cannot be used to measure
of myelin cholesterol and lipid metabolism (2). Apolipo- very small amounts of apolipoprotein B in CSF. Enzyme
protein B is involved in the mediation of lipoprotein linked immunosorbent assays (ELISA) and radio-
binding, uptake and cholesterol delivery via low density immunoassay (RIA) are sensitive, but the linear working
lipoprotein (LDL) receptors. Although LDL receptors range of the curve of ELISA is small (10, 11) and RIA
have been described on oligodendrocytes (1), apolipo- requires a radiolabelling license (12). To measure apoli-
protein B was thought to be absent (1, 3) or present in poprotein B in CSF, we have developed a very sensitive
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method: time-resolved immunofluorometric assay (TR-
IFMA) using europium as label. The value of TR-IFMA
for the measurement of proteins present in small
amounts in CSF has been reported elsewhere (13-15).
The reliability of TR-IFMA for the measurement of
apolipoprotein B was first studied in serum. A compara-
tive study was then performed with an electroimmuno-
diffusion on serum and CSF samples. Because usual
techniques are not sensitive enough to measure small
amounts of apolipoprotein B, a comparative study was
performed immunonephelometrically with serum sam-
ples from normolipidaemic and dyslipidaemic subjects.
CSF and serum apolipoprotein B concentrations were
then determined in subjects free of neurological disor-
ders and in patients with multiple sclerosis. Local in-
trathecal apolipoprotein B synthesis was calculated.
Materials and Methods
Study population
Three groups of patients were studied
The first group (group A) consisted of 24 controls (7 women, 17
men, average age: 42 ± 13 years, range: 22-63) to determine the
reference range of apolipoprotein B in CSF. These samples were
then used in a comparison between TR-IFMA and electroimmu-
nodiffusion. None of the controls had an increased immunoglobulin
G (IgG) index or an oligoclonal band in their CSF, and none had
evidence of active demyelinating disease. The integrity of the
blood-brain barrier was assessed by measuring albuminorachia (se-
rum albumin: 43164 ± 5466 mg/1; CSF albumin: 228.5 ± 78.4
mg/1). None of the controls had dyslipoproteinaemia (cholesterol:
4.65 ± 1.98 mmol/1; triacylglycerols: 1.56 ± 0.37 mmol/1).
The second group (group B) was composed of 30 multiple sclerosis
patients (24 women, 6 men, average age: 39 ± 15, range: 29-65)
with an increased IgG index and oligoclonal banding in CSF. None
had important blood-CSF barrier damage (serum albumin: 42530
± 6221 mg/1; CSF albumin: 250.0 ± 98.0 mg/1) or dyslipoprotein-
aemia (cholesterol: 4.80 ±0.2 mmol/1; triacylglycerols: 1.76
± 0.23 mmol/l).
Paired serum and CSF samples were collected during a single 24 h
period and stored at -70 °C until analysis.
The third group (group C) consisted of 94 subjects, whose sera
were used for an intermethod comparison of apolipoprotein B val-
ues in serum between TR-IFMA and immunonephelometry. Thirty-
seven subjects with a mean (± standard deviation) cholesterol con-
centration of 5.18 ± 0.63 mmol/1 (range: 4.10-5.90 mmol/1) and
triacylglycerol concentrations of 1.02 ±0.29 mmol/1 (range:
0.48-1.35 mmol/1) formed the normolipidaemic subgroup.
Twenty-five subjects with mean cholesterol concentrations of 7.49
±1.10 mmol/1 (range: 6.20-10.80 mmol/1) and triacylglycerol
concentrations of 1.10 ± 0.21 mmol/1 (range: 0.71-1.40 mmol/1)
formed the hypercholesterolaemic subgroup. Thirty-two subjects
with a mean cholesterol concentration of 5.15 ±0.94 mmol/1
(range: 2.80 ± 6.50 mmol/1) and triacylglycerolaemia of 3 02
± 1.36 mmol/1 (range: 1.61-7.36 mmol/1) formed the hypertria-
cylglycerolaemic subgroup. Sera were stored at 4 °C for 24 h until
being assayed.
Measurement of apolipoprotein B by TR-IFMA
Apparatus
We used a time-resolved fluorometer (1230 Arcus™), a 12-well
aspirating-washing device (1296-024 Platewash), and an automated
shaker (1296-001 Plateshake), all from Pharmacia (Uppsala, Swe-
den).
Reagents
We used a purified rabbit anti-human apolipoprotein B IgG anti-
body (Interservice B. M., Brazzaville, Boriin) in phosphate buffer
(0.1 mol/I, pH 7.4). Delfia™ europium-labeling kits were
purchased from Pharmacia. Each kit contains 0.2 mg of label-
ing reagent (Nl -(p-isothiocyanatobenzyl)-diethylenetriamine-
A^A^,^W3-tetraacetate-eiiropium), a 100 nmol/I europium stan-
dard, highly purified bovine serum albumin (5 g/1 in Tris-HCl 50
mmol/1, pH 7.8, NaN3, 0.5 g/1), stabilizer, and enhancement solu-
tion (per litre, 15 mmol 2-naphthoyltrifluoroacetone, 50 mmol tri-
H-octylphosphine oxide, 100 mmol acetic acid, 6.8 mmol potas-
sium hydrogen phthalate, and 1.0 g of Triton X-100 detergent). PD-
10 columns were from Pharmacia.
Buffers
The labeling buffer was 50 mmol/1 NaHCO3, pH 8.5, containing
9 g/1 NaCl. The elution buffer was 50 mmol/1 Tris-HCl, pH 7.8,
containing 9 g/l NaCl and 0.5 g/1 NaN3. The coating buffer was
K2HPO4 (50 mmol/1, pH 8.5), and the saturation solution was 50
mmol/1 NaH2PO4, 2 H2O, 60 g/1 sorbitol arid 5 g/1 bovine serum
albumin. The dilution buffer was 50 mmol/1 Tris-HCl, pH 7.75,
9 g/1 NaCl, 5.0 g/1 bovine serum albumin, 0.5 g/1 bovine γ-globulin,
100 mg/1 Tween 40, and 20 μιηοΐ/ΐ di-ethylene-triaminopentaacetic
acid. The washing solution was 100 mmol/1 Tris-HCl, pH 7.75,
with 3 g/1 Tween 20. * *~
Standard
Human serum standard OKTL (Behring, Marburg, Germany),
which has an apolipoprotein B concentration of 1.15 g/1, was di·^
luted with buffer to obtain six standard concentrations.
Labeling
Purified rabbit anti-human apolipoprotein B IgG antibodies (150
μΐ) were loaded onto a PD 10 column rinsed with labeling buffer.
Fractions of 500 μΐ were collected and protein absorbance was
measured at 280 nm with an Ultraspec II (Pharmacia). The fraction
corresponding to peak absorbance (about 2.5 ml of elution buffer)
containing about 1.0 g/1 IgG (an absorbance value of 1.34 corre-
sponding to 1 g/1 IgG). A volume of 250 μΐ (0.25 mg IgG) was
added to 0.05 mg of labeling reagent (containing the europium^·
chelate) and incubated overnight at room temperature with gentle
stirring.
Purification of europium-labeled IgG
The preparation was purified by gel filtration through a PD-10 col-
umn and eluted with elution buffer. Ten 1-ml fractions were col-
lected and absorbance was read at 280 nm. Fractions corresponding
to peak IgG absorbance were pooled.
Characterization of europium-labeled IgG
The amount of europium-labeled antibody bound to anti-apolipo-
protein B was determined by measuring europium fluorescence rel-
ative to that of the europium chloride standard (100 nmol/1). After
addition of enhancement solution, the fluorescence of the euro-^
pium-2-naphthoyl trifluoroacetone chelate was measured as counts
per second in a time-resolved fluorometer. The protein content of
the europium-labeled antibody was quantified after measuring ab-
sorbance at 280 nm as:
Protein (mol/1) = A280 - (0.008 Χ Ειί) Χ 106/Α Χ Mr
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(A28(l· absorbance of eluted fraction at 280 nm, 0.008: absorbance
of bound aromatic thiourea, Eu: amount of europium (mmol/1), A:
absorbance of IgG (1.34), Mr: relative molecular mass of IgG
(160000)).
The europium/protein ratio was used to calculate the conjugation
yield (7 europium molecules per IgG molecule). The labeled anti-
body was stored with stabilizer to improve the stability of the euro-
pium-labeled IgG. There was no loss of immunoreactivity during
six months of storage at 4 °C.
Coating of microtitre plates
Unlabeled anti-apolipoprotein B IgG was diluted in buffer to a final
concentration of 100 mg/1. Polystyrene microtitre plates (Micro-
well™, Nunc Inc., Naperville, USA) were coated by adding 200
μ] of the antibody solution per well and incubating the plates for
l h at 37 °C. The wells were then washed three times with 250 μΐ
of saturation solution per well to block non-specific binding sites,
aspirated and used immediately.
Immunoassay procedure
Human serum standard dilutions were made in dilution buffer from
10~6 to 2.5 X 10~2. Serum and CSF samples were also diluted in
dilution buffer to 2.5 X 10~5 and 10"1, respectively. Two hundred
μΐ of each dilution was placed in duplicate wells and incubated for
2 h at room temperature on an automated shaking device. The reac-
tion was stopped by washing the wells six times with washing
solution, using the 12-well aspirating-washing device. Europium-
labeled anti-apolipoprotein B antibody was diluted to a final con-
centration of 250 μ^/Ι in assay buffer, then 200 μΐ was added per
well and incubated for l h at room temperature with gentle shak-
ing. The reaction was stopped as described above. The amount
of labeled antibody bound to apolipoprotein B was quantified by
dissociating europium from the antibody with enhancement solu-
tion (200 μΐ per well), followed by 10 min incubation with shaking
and a further 10 min without shaking. The fluorescence of euro-
pium — 2-naphthoyltrifluoroacetone acetate was measured as
counts per second in the time-resolved fluorometer. The instru-
ment's data-reduction program was used to calculate the concentra-
tion of apolipoprotein B in the samples.
Criteria of reliability
Linearity
The linearity of the method was determined using the human serum
standard diluted to apolipoprotein B concentrations between 1.15
and 57 500 μg/L Each dilution was assayed six times in three sepa-
rate runs.
Detection limit
The lower detection limit of the assay was defined as the concen-
tration corresponding to the mean plus 3 standard deviations of the
zero standard fluorescence signal (for 15 replicates in 5 analytical
runs).
-tnlermethod comparison
A comparative study was performed with an electroimmunodifru-
sion assay with serum and CSF samples for patients from groups
A and B, and with an immunonephelometric technique (BNA, Beh-
ringwerke, Marburg, Germany) with serum samples from normoli-
pidaemic and dyslipidaemic subjects.
Immunoreact ivi ty of anti-apolipoprotein B antibodies
with apolipoprotein B in isolated LDL and serum
LDL of the density range of 1.03 — 1.05 kg/dm3 was obtained by
ultracentrifugation of serum from normolipidaemic subjects (16).
Isolated LDL was dialyzed against dilution buffer (pH 7.75). Apo-
lipoprotein B in the isolated LDL fraction was then measured by
immunonephelometry (apolipoprotein B: 0.9 g/1) and stored at 4 °C
for 24 h. Curves of fluorescence intensities versus dilutions of iso-
lated LDL and human serum standard (apolipoprotein B: 1.15 g/1)
were constructed. Their slopes were compared to test the immuno-
reactivity of the anti-apolipoprotein B antibodies used in the TR-
IFMA.
Comparison of dose-response curves for
apolipoprotein B in serum and CSF
Dose-response curves (apolipoprotein B concentration versus fluo-
rescence counts) were constructed for serum and CSF.
Other assays
Albumin and IgG were determined in serum and CSF by means of
electroimmunodiffusion as previously described (17). Serum sam-
ples were analysed for cholesterol and triacylglycerols by enzy-
matic methods with a SMAC Il-analyser™ (Bayer Diagnostics,
Puteaux, France).
Evaluation of intrathecal synthesis
The blood/CSF ratio of apolipoprotein B was calculated. An index
analogous to the CSF IgG index was calculated as follows:
Apolipoprotein B index = (CSF apolipoprotein B/serum apolipo-
protein B)/(CSF albumin/serum albumin).
Local intrathecal apolipoprotein B synthesis was calculated using
the formula of Schuller (18), as:
if CSF albumin ^ 210 mg/1, local intrathecal apolipoprotein B syn-
thesis = CSF apolipoprotein B - 200;
if CSF albumin > 210 mg/1, local intrathecal apolipoprotein B
synthesis = CSF apolipoprotein B - (200 + ({CSF albumin
- 210}/153) X (serum apolipoprotein B)). In this formula, 200 is
the upper limit of normal filtration of apolipoprotein B and 153 the
transudation equivalence of apolipoprotein B related to its relative
molecular mass (549 000) comparatively to albumin transudation;
210 mg/1 is the mean reference value of CSF albumin.
Precision
The intra-assay precision of the TR-IFMA method was studied by
analysing the human serum standard at three apolipoprotein B con-
centrations (11.5, 115 and 575 ^g/l) 20 times each. Inter-assay
precision was studied by analysing control solutions at two apoli-
poprotein B concentrations (11.5 and 575 μg/l) 15 times each over
a period of three weeks.
Statistical analysis
The serum apolipoprotein B concentrations obtained by TR-IFMA
and immunonephelometry were compared using the Mann and
Wliitney non-parametric test. Intermethod comparisons were made
by using the Spearman rank test and a regression line was plotted.
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Results
Criteria of re l i ab i l i ty
Linearity
The method was linear for apolipoprotein B concentra-
tions between 3 μg/l and 11 500 μ§/1. In standard use,
the calibration curve for the human serum standard can
be established at apolipoprotein Β concentrations from
3μ§/1ίο 1150 μ§/1 (fig. 1).
Detection limit
The lower detection limit of the TR-IFMA for apolipo-
protein B was 0.3 μg/l.
Precision
The within-run coefficients of variation (CVs) were
12.5% for 11.5 μ§/1, 5.8% for 115 μ§/1 and 5.2% for 575
μg/l apolipoprotein B. The between-run CVs were
15.2% for 11.5 μ§/1 and 8.2% for 575 μg/l apolipopro-
tein B.
0.0 O.S 1.0 1.5 2.0 2.5
Apolipoprotein B (immunonephelometry) [g/1]
Fig. 2 Correlation between TR-IFMA and immunonephelometry
for the measurement of apolipoprotein B in normolipaemic (A)
(y = 0.93x +0.10; r = 0.82), hypercholesterolaemic (D)
(y = 0.47x + 0.40; r = 0.82) and hypertriacylglycerolaemic sub-
jects (O) (y = 0.91x - 0.04; r = 0.91) (group C).
Intermethod comparison
No apolipoprotein B was detected in CSF by means of
electroimmunodiffiision with a detection limit of 1 mg/1.
In serum, there was good positive agreement between
TR-IFMA and electroimmunodiffusion in group A and
B (r = 0.65; p < 0.01). There was also good positive
1150 pg/1
10
10
Apolipoprotein
Fig. 1 Calibration curve for the measurement of apolipoprotein
B by TR-IFMA - Serum standard OKTL (Behring, Marburg Ger-
many), apolipoprotein B: 1.15 g/1.
agreement between TR-IFMA and immunonephelomet-
ric apolipoprotein B values for all the subjects in group
C (p < 0.001) and in each subgroup (normolipidaemic,
hypercholesterolaemic and hypertriacylglycerolaemic)
(p < 0.001) (fig. 2). The mean serum apolipoprotein B
concentrations in normolipidaemic subjects were 1.02
g/1 and 1.01 g/1 by TR-IFMA and immunonephelometry,
respectively. The mean apolipoprotein B concentration
in the subjects with hypercholesterolaemia was slightly
lower by TR-IFMA than by immunonephelometry
(p < 0.05) (1.27 g/1 and 1.44 g/1, respectively). The TR-
IFMA apolipoprotein B concentration was 15% lower
than the immunonephelometric value for apolipoprotein
B < 1.4 g/1 and 14% lower for apolipoprotein B > 1.4
g/1. The mean apolipoprotein B concentration in the sub-
jects with hypertriacylglycerolaemia was lower by TR-
IFMA than by immunonephelometry (p < 0.001) (1.03
g/1 and 1.36 g/1, respectively). The TR-IFMA apolipo-
protein B concentration were 27% lower than immuno-
nephelometric values for apolipoprotein B < 1.4 g/1 and
42% lower for apolipoprotein B > 1.4 g/1.
Immunoreactivity of the anti-apolipoprotein
B antibodies with apolipoprotein B in isolated
LDL and serum
The slopes of the curves for fluorescence counts versus
dilutions of isolated LDL and human serum standard
OKTL were similar at apolipoprotein B concentrations
from 225 to 9000 μg/L The dose-response curves for
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serum and CSF apolipoprotein B concentrations were
identical (data not shown).
CSF and serum apolipoprotein B
concentrations, apolipoprotein B blood/CSF
ratio, index and local intrathecal synthesis in
groups A and B
Table 1 gives the means and standard deviations for the
serum and CSF apolipoprotein B and albumin concen-
trations and the apolipoprotein B blood/CSF ratio, index
and local intrathecal synthesis in groups A and B. There
was a highly significant correlation between CSF apo-
lipoprotein B and CSF albumin (r = 0.79; p < 0.001) in
group A and (r = 0.65; p < 0.005) in group B. There
was also a significant correlation between CSF apolipo-
protein B and albumin quotient (r = 0.77 in group A
and r = 0.71 in group B; p < 0.001). There were no dif-
ferences between the two groups in any of the quanti-
ties studied.
Discussion
Several immunoassays have been used for the measure-
ment of apolipoprotein B in serum (19). These assays
are usually not sensitive enough for the measurement of
small amounts of apolipoprotein B in other body fluids
such as CSF. In addition, the most suitable for routine
use, immunoturbidimetry and immunonephelometry, are
subject to interference by turbidity in the sample (20).
In order to measure apolipoprotein B in CSF, we devel-
oped a highly sensitive method, TR-IFMA. Reliability
was satisfactory. The sensitivity of the TR-IFMA (0.06
X 10~3 g/well) was better than that of RIA (0.3 - 10
X 10~3 g/well) and ELISA (0.1 - 0.5 X 1(T3 g/
well) (21), owing to both the retained immunoreactivity
of the chelate-labelled antibodies and the highly sensi-
tive time-resolved fluorescent detection method for en-
hanced chelate fluorescence (22). The working range
was large, contrary to ELISA (11), and within- and be-
tween-run precision was good. A correlation was ob-
tained between TR4FMA and electroimmunodiffusion
in serum and immunonephelometry for serum apolipo-
protein B concentrations in group C. The mean apolipo-
protein B concentrations obtained with TR-IFMA
matched those obtained by immunonephelometry in the
normolipidaemic and hypercholesterolaemic subgroups.
The higher values obtained by immunonephelometry in
the hypertriacylglycerolaemic subgroup could be related
to the difference observed between one-site (nephelome-
try) and two-site (TR-IFMA) assays (23). These higher
values could be due to the sensitivity of the nephelomet-
ric method to the size of the analyte, owing to differ-
ences in light scattering (24). Indeed, the measurement
of apolipoprotein B can be inaccurate in samples con-
taining large triacylglycerol-rich particles (12). The
overestimation of apolipoprotein B by immunonephe-
lometry in hypertriacylglycerolaemic serum is overcome
by TR-IFMA which, by measuring fluorescence, is inde-
pendent of sample turbidity (25).
The equal immunoreactivity of the anti-apolipoprotein
B antibodies with apolipoprotein B in different forms
(serum and isolated LDL), and the equal dose-response
curves for serum and CSF apolipoprotein B, makes this
method well adapted to the quantification of apolipo-
protein B in CSF.
The sensitivity of TR-IFMA was sufficient to detect
small amounts of apolipoprotein B in CSF from all the
patients studied. No apolipoprotein B was detected in
CSF by electroimmunodiffusion (detection limit:
1 mg/1). These observations are in agreement with re-
ports by Roheim et al. (3) and Pitas et al. (1). Using a
sensitive ELISA, Carlson et al. also reported the pres-
ence of apolipoprotein B in CSF (4). The higher CSF
apolipoprotein B concentrations described by Carlson
(0.77 ± 3.4 mg/1 versus 0.12 ± 0.06 mg/1 in our study)
could be explained by difference in the patients studied.
Indeed, these authors studied only neurological patients
with large variations in CSF albumin, i. e. with blood-
CSF barrier damage. No differences were observed in
serum and in CSF apolipoprotein B concentrations be-
tween controls and multiple sclerosis patients, none of
whom had increased blood-CSF barrier permeability. As
Carlson reported, CSF apolipoprotein B concentrations
were several orders of magnitude lower than the corre-
sponding serum concentrations: the blood/CSF ratios
Tab. 1 Concentrations of quantities studied in control subjects (group A) and multiple sclerosis
patients (group B)
Serum apolipoprotein B (mg/1) CSF apolipoprotein B (mg/l)
Group A
Group B
TR-IFMA
934 ± 180*
886 ± 219
EID
1149 ±298
1387 ± 456
TR-IFMA EID
0.11 ±0.06 <1
0.12 ±0.06 <1
Blood/CSF ratio
5920 ± 1751
6928 ± 3205
Index
0.31 ±0.19
0.34 ±0.21
* Mean ± standard deviation
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were about 6000 in both controls and multiple sclerosis
patients. As presumed from these very high blood/CSF
ratios, no apolipoprotein B intrathecal synthesis was
found by determination of both apolipoprotein B index
and local intrathecal synthesis in either group A or B.
Moreover, the CSF apolipoprotein B concentrations
showed a good correlation with the albumin quotient
and the albumin level in CSF, indicating that the small
amounts of apolipoprotein B in CSF are presumably of
serum origin. It is noteworthy the Blue et al. found no
apolipoprotein B synthesis in the rooster brain (26).
The excellent reliability of this technique, particularly
its high sensitivity, makes it suitable for the measure-
ment of apolipoprotein B in CSF and other fluids con-
taining very low concentrations of apolipoprotein B.
Moreover, a very small volume of CSF (20 ) is re-
quired. The very small amounts of apolipoprotein B in
CSF indicate its probable serum origin, while the lack of
differences between the controls and multiple sclerosis
patients calls into question the role of this apolipoprotein
in lipid transport in the central nervous system.
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